Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03646370 · ClinicalTrials.gov registry record
Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen
A clinical trial of Cardiovascular Diseases and Metabolic Syndrome, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 110
- Enrollment target
- 1
- Study location
NCT03646370: Completed study of Cardiovascular Diseases and Metabolic Syndrome, sponsored by Thomas Jefferson University.
NCT03646370 is a study of Cardiovascular Diseases and Metabolic Syndrome that has completed, run by Thomas Jefferson University. The registered enrollment target is 110 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03646370, a study of Cardiovascular Diseases and Metabolic Syndrome, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
Switching patients with HIV infection from tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF) based drug regimen can provide many safety benefits including preserving bone mineral density and kidney function. This study will examine metabolic changes that patients may encounter due to the switch in medication regimens and the maintenance of viral suppression.
Primary Outcome
Changes in weight will be determined through comparisons of average baseline and endpoint weights
Conditions Studied
Interventions
- DRUG Tenofovir Alafenamide
Study Locations (1)
Pennsylvania
- Thomas Jeffeson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2019-07-24 |
What the finished NCT03646370 record still lists
NCT03646370 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Tenofovir Alafenamide is the first listed.
NCT03646370 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03646370 about?
NCT03646370 is a clinical study titled "Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen". Switching patients with HIV infection from tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF) based drug regimen can provide many safety benefits including preserving bone mineral density and kidney function. This study will examine metabolic changes that patients may encounter due...
What is the current status of trial NCT03646370?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2018-07-25. Estimated completion is 2019-07-24.
What conditions does trial NCT03646370 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Metabolic Syndrome, HIV-1-infection, Hyperglycemia, Weight Gain.
What interventions are being tested in trial NCT03646370?
The interventions under investigation include: Tenofovir Alafenamide (DRUG).
Who is sponsoring clinical trial NCT03646370?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03646370 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03646370's enrollment target sits among peer trials
110 189th of 300 higher than 112 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)
RECRUITING
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI